Emaglin-L 10 mg+5 mg (Tablet)

Unit Price: ৳ 30.00 (3 x 7: ৳ 630.00)

Strip Price: ৳ 210.00

Medicine Details

Emaglin-L is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Recommended dose: 10 mg Empagliflozin and 5 mg Linagliptin once daily, taken in the morning, with or without food.
Increased dose: Dose may be increased to 25 mg Empagliflozin and 5 mg Linagliptin once daily.
Renal impaired patients: Assess renal function before initiating this tablet.
Do not initiate this tablet if eGFR is below 45 mL/min/1.73 m2.
Discontinue taking this tablet if eGFR falls below 45 ml/min/1.73 m2.

Diuretics: Coadministration of Empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion.
Insulin or Insulin Secretagogues: Coadministration of Empagliflozin with Insulin or Insulin secretagogues increases the risk for hypoglycemia.
Inducers of P-glycoprotein or CYP3A4 Enzymes: Rifampin decreased Linagliptin exposure, suggesting that the efficacy of Linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer.
Positive Urine Glucose Test: SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests.
Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors.

Severe renal impairment, end-stage renal disease, or dialysis
History of hypersensitivity reaction to Linagliptin, such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity
History of serious hypersensitivity reaction to Empagliflozin

Not recommended during the second and third trimesters of pregnancy.
The limited available data of this tablet in pregnant women are not sufficient to determine a drug-associated risk for major birth defects and miscarriage.
There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy.

Pancreatitis: Acute pancreatitis, including fatal pancreatitis, has been reported in patients treated with Linagliptin.
Ketoacidosis: Reports of ketoacidosis, a serious life-threatening condition requiring urgent hospitalization have been identified in clinical trials and postmarketing surveillance in patients with type 1 and type 2 diabetes mellitus receiving sodium glucose co-transporter-2 (SGLT2) inhibitors, including Empagliflozin.
Volume Depletion: Empagliflozin can cause intravascular volume depletion which may sometimes manifest as symptomatic hypotension or acute transient changes in creatinine.

In the event of an overdose with this tablet, contact Poison Control Center.
Employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as dictated by the patient’s clinical status.
Removal of Empagliflozin by hemodialysis has not been studied, and removal of Linagliptin by hemodialysis or peritoneal dialysis is unlikely.